Danaher (NYSE:DHR) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Danaher (NYSE:DHR) released its earnings results on Tuesday. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20, Briefing.com reports. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.36 EPS.

Danaher Trading Down 1.8 %

DHR opened at $245.82 on Friday. Danaher has a twelve month low of $182.09 and a twelve month high of $259.00. The company has a 50-day simple moving average of $248.94 and a 200 day simple moving average of $230.88. The company has a quick ratio of 1.37, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $182.08 billion, a price-to-earnings ratio of 41.66, a P/E/G ratio of 4.19 and a beta of 0.83.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is presently 18.31%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Raymond James increased their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Barclays upped their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday. KeyCorp increased their price objective on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. TD Cowen raised their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Citigroup increased their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $270.00.

Insider Buying and Selling

In other news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Teri List sold 3,289 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the sale, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Insiders sold 84,132 shares of company stock valued at $21,022,795 over the last quarter. 11.10% of the stock is owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.